[HTML][HTML] COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
P Maisonnasse, Y Aldon, A Marc, R Marlin… - Nature …, 2021 - hal.science
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
P Maisonnasse, Y Aldon, A Marc, R Marlin… - Nature …, 2021 - ideas.repec.org
Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-
2) are urgently needed. Monoclonal antibodies have shown promising results in patients …
2) are urgently needed. Monoclonal antibodies have shown promising results in patients …
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.
P Maisonnasse, Y Aldon, A Marc… - Nature …, 2021 - search.ebscohost.com
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
P Maisonnasse, Y Aldon, A Marc… - Nature …, 2021 - researchexperts.utmb.edu
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
RL Grand, P Maisonnasse, Y Aldon, A Marc… - Research …, 2021 - researchsquare.com
One year into the Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe
Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), effective treatments are still …
Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), effective treatments are still …
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
P Maisonnasse, Y Aldon, A Marc… - Nature …, 2021 - econpapers.repec.org
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
P Maisonnasse, Y Aldon, A Marc, R Marlin… - Nature …, 2021 - hcl.hal.science
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
[PDF][PDF] COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
P Maisonnasse, Y Aldon, A Marc, R Marlin… - researchgate.net
Results COVA1-18 in vitro potency is dependent on avidity. To advance our earlier in vitro
results 9 on COVA1-18 and allow for better comparability with other studies, we used two …
results 9 on COVA1-18 and allow for better comparability with other studies, we used two …
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
P Maisonnasse, Y Aldon… - Nature …, 2021 - researchinformation.amsterdamumc …
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …
(SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results …